September 27, 2020

Cancer Gene Therapy Market Worth US$ 3.2 Bn by 2026

According to Acumen Research and Consulting, the worldwide Cancer Gene Therapy market expected to surpass US$ 3.2 Bn by 2026, increasing at a CAGR of 29.7% between 2019 and 2026.

CLICK HERE FOR FREE SAMPLE REPORT
https://www.acumenresearchandconsulting.com/request-sample/1670

Recent global market survey Cancer Gene Therapy involves various industry organizations from different geographies to generate a report of more than 100 pages. The study is an optimal combination of quality and quantitative data which illustrates major market trends, challenges facing by industry and company, as well as gap analysis and new opportunities with trends on the Cancer Gene Therapy market. The research links historical data for 2015-2018 and forecasts up to 2026. The objective of this research is to present an application; type and geographical region evaluation of the worldwide Cancer Gene Therapy market–Regions include North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

For Exclusive Offer !!! Contact Us  sales@acumenresearchandconsulting.com | +1 407 915 4157

The research is also aimed at delivering the recent market intelligence and helping decision makers make sound investment evaluations, as well as defining and analyzing changing trends and key drivers, challenges & opportunities. We have also implemented significant company rivals who penetrate the global Cancer Gene Therapy market with major strategies and competitive landscape to evaluate the situation of players currently. The study also identifies the qualitative effect on market segmentation and geographical regions of distinct market variables. Thus, the research builds the attractiveness of each important segment over the forecast period.

This research includes a thorough 360-degree analysis on the Cancer Gene Therapy market, which provides insight into possibilities and difficulties for the stakeholders. It monitors the worldwide Cancer Gene Therapy market in developed economies and provides detailed comment and precise quantitative insight. The research also involves incisive competitive landscape analyzes and offers important market players suggestions on effective imperatives and strategies.

Market Participants

The players profiled in the report include Vigene Biosciences, Sirion Biotech, bluebird bio, Cellectis, and Ziopharm, Cobra, Finvector, Sangamo Therapists Inc., Novartis AG, Sarepta Therapeutics, and Caribou among others.

Market Segmentation

Market By Type

  • Ex-vivo
  • In-vivo

Market By Product

  • Viral Vectors
  • Non-viral Vectors
  • Others

Market By End-use

  • Biopharma companies
  • Research Institutes
  • Others

Market By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cancer Gene Therapy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Gene Therapy Market By Type
1.2.2.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Cancer Gene Therapy Market Revenue Share By Type in 2017
1.2.2.3. Ex-vivo
1.2.2.4. In-vivo
1.2.2.5. Others
1.2.3. Cancer Gene Therapy Market By Product
1.2.3.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.3.2. Global Cancer Gene Therapy Market Revenue Share By Product in 2017
1.2.3.3. Viral Vectors
1.2.3.4. Non-viral Vectors
1.2.3.5. Others
1.2.4. Cancer Gene Therapy Market By End-Use
1.2.4.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Global Cancer Gene Therapy Market Revenue Share By End-Use in 2017
1.2.4.3. Hospitals
1.2.4.4. Biopharma companies
1.2.4.5. Research Institutes
1.2.4.6. Others
1.2.5. Cancer Gene Therapy Market By Geography
1.2.5.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cancer Gene Therapy Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Cancer Gene Therapy Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Cancer Gene Therapy Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Cancer Gene Therapy Major Manufacturers in 2017

CHAPTER 4. CANCER GENE THERAPY MARKET By TYPE
4.1. Global Cancer Gene Therapy Revenue By Type
4.2. Ex-vivo
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. In-vivo
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. CANCER GENE THERAPY MARKET BY PRODUCT
5.1. Global Cancer Gene Therapy Revenue By Product
5.2. Viral Vectors
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Non-viral Vectors
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. CANCER GENE THERAPY MARKET BY END-USE
6.1. Global Cancer Gene Therapy Revenue By End-Use
6.2. Hospitals
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Biopharma companies
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Research Institutes
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA CANCER GENE THERAPY MARKET BY COUNTRY
7.1. North America Cancer Gene Therapy Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Cancer Gene Therapy Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE CANCER GENE THERAPY MARKET BY COUNTRY
8.1. Europe Cancer Gene Therapy Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC CANCER GENE THERAPY MARKET BY COUNTRY
9.1. Asia-Pacific Cancer Gene Therapy Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA CANCER GENE THERAPY MARKET BY COUNTRY
10.1. Latin America Cancer Gene Therapy Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST & Africa CANCER GENE THERAPY MARKET BY COUNTRY
11.1. Middle East & Africa Cancer Gene Therapy Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East & Africa Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 – 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Vigene Biosciences
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Sirion Biotech
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Bluebird Bio
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Cellectis
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Ziopharm
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Cobra
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Finvector
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sangamo Therapists Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Novartis AG
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Sarepta Therapeutics
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Caribou
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Others
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope


REQUEST CUSTOMIZATION
https://www.acumenresearchandconsulting.com/request-customization/1670

BUY THIS PREMIUM REPORT
https://www.acumenresearchandconsulting.com/buy-now/0/1670

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us

Sheetal K     –     LinkedIN | Twitter
https://www.acumenresearchandconsulting.com
+14079154157 | +14089009135

THOMAS ROBBINS

is a freelancer, a graduate of the University of Pennsylvania with a BA in English, he studied accounting at the Wharton School of Business, and currently lives in Staten Island has been covering business and technology for a variety of publications since 1989. He worked for Red Herring, Beyond Computing & Accounting Technolgy. He covers accounting, taxes, finance, government news & technology for the site Mail me

thomasrobbins@globepredict.com

View all posts by THOMAS ROBBINS →

Leave a Reply

Your email address will not be published. Required fields are marked *